Truist analyst David MacDonald lowered the firm’s price target on UnitedHealth (UNH) to $370 from $410 and keeps a Buy rating on the shares. The firm is adjusting its estimates after the company’s Q4 results and 2026 guidance, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- UnitedHealth price target lowered to $389 from $425 at JPMorgan
- UnitedHealth’s Sharp Sell-Off Has Wall Street Divided
- Option traders moderately bearish in UnitedHealth with shares down 1.97%
- UnitedHealth price target lowered to $370 from $400 at Wells Fargo
- UnitedHealth price target lowered to $327 from $391 at Barclays